. Summary for Patients: Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes. Ann Intern Med 2025 Jun 17. doi: 10.7326/ANNALS-24-00775.
PMID: 40523285